Study title: Phase I-II study of high-dose fotemustine followed by autologous peripheral blood stem-cell transplant in children and adolescents with relapsed or refractory malignant solid tumours
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Immune System Diseases | |||||
| Brands: Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: FOTEMUSTINE | |||||
| ATC code: L01A D05 | |||||
| Document link: fotemustine_CL1-10036-305_spreadsheet.xls | |||||
| Document date: 2011-11-07 | |||||
| Study number: CL1-10036-305 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |